Tsuzuki, S., Nakanishi, S., Tamaki, M., Oshiro, T., Miki, J., Yamada, H., . . . Egawa, S. (2021). Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. Public Library of Science (PLoS).
Style de citation Chicago (17e éd.)Tsuzuki, Shunsuke, et al. Initial Dose Reduction of Enzalutamide Does Not Decrease the Incidence of Adverse Events in Castration-resistant Prostate Cancer. Public Library of Science (PLoS), 2021.
Style de citation MLA (8e éd.)Tsuzuki, Shunsuke, et al. Initial Dose Reduction of Enzalutamide Does Not Decrease the Incidence of Adverse Events in Castration-resistant Prostate Cancer. Public Library of Science (PLoS), 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.